RBC Capital Reiterates Outperform on Merck & Co, Maintains $142 Price Target

Benzinga Newsdesk www.benzinga.com Negative 90.9%

Neg 90.9% Neu 0% Pos 0%

RBC Capital analyst Trung Huynh reiterates Merck & Co (NYSE:MRK) with a Outperform and maintains $142 price target.

Comments

No comments yet. Be the first!